Armistice Capital LLC Has $2.78 Million Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Armistice Capital LLC cut its stake in Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) by 46.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,136,000 shares of the company's stock after selling 1,820,000 shares during the period. Armistice Capital LLC owned about 2.86% of Clearside Biomedical worth $2,777,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CLSD. SG Americas Securities LLC acquired a new position in Clearside Biomedical during the first quarter worth $49,000. International Assets Investment Management LLC acquired a new stake in shares of Clearside Biomedical during the 1st quarter worth about $57,000. XTX Topco Ltd lifted its holdings in Clearside Biomedical by 172.2% during the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company's stock valued at $71,000 after purchasing an additional 34,359 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Clearside Biomedical in the second quarter valued at about $368,000. Finally, Renaissance Technologies LLC grew its stake in Clearside Biomedical by 6.6% during the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company's stock worth $757,000 after buying an additional 35,900 shares during the last quarter. Institutional investors own 18.75% of the company's stock.

Clearside Biomedical Trading Up 1.8 %

Shares of CLSD traded up $0.02 during trading hours on Friday, hitting $1.16. 93,397 shares of the stock traded hands, compared to its average volume of 273,731. The business has a fifty day moving average of $1.11 and a 200-day moving average of $1.26. The firm has a market capitalization of $86.69 million, a PE ratio of -2.11 and a beta of 2.34. Clearside Biomedical, Inc. has a 1-year low of $0.65 and a 1-year high of $2.12.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.25 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. As a group, equities research analysts expect that Clearside Biomedical, Inc. will post -0.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Clearside Biomedical in a report on Tuesday, August 27th. Chardan Capital began coverage on Clearside Biomedical in a research note on Wednesday, August 21st. They issued a "buy" rating and a $6.00 price objective on the stock. Oppenheimer assumed coverage on Clearside Biomedical in a research note on Tuesday, June 25th. They issued an "outperform" rating and a $5.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $4.00 price objective on shares of Clearside Biomedical in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $4.83.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.